Eight weeks be­tween each HIV treat­ment? GSK notch­es PhI­II win as it chas­es OK for long-act­ing reg­i­men

GSK has cleared an­oth­er test in its grand plan to top­ple Gilead’s HIV dom­i­nance by of­fer­ing al­ter­na­tive treat­ments that con­sist of few­er drugs and last longer. A year af­ter scor­ing pos­i­tive Phase III da­ta on a four-week course of cabote­gravir and rilpivirine, its Vi­iV sub­sidiary now says that an eight-week reg­i­men seem to work just as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER